Mvasi and Kanjinti Now Available in the United States
July 19, 2019
Amgen and Allergan have announced the U.S. launch of Mvasi (bevacizumab-awwb), a biosimilar to Avastin (bevacizumab), and Kanjinti (trastuzumab-anns), a biosimilar to Herceptin (trastuzumab).
Mvasi was approved in September 2017 for the treatment of five types of cancer. It is the first biosimilar Avastin product available in the United States.
Kanjinti was approved in June 2019 for all approved indications of Herceptin. It is the first biosimilar Herceptin product available in the United States.
The Wholesale Acquisition Cost (WAC) of both Mvasi and Kanjinti will be 15% lower than their reference products. Mvasi is being made available at a WAC of $677.40 per 100 mg and $2,709.60 per 400 mg single-dose vial, 15% less than the WAC for Avastin. Kanjinti is being made available at a WAC of $3,697.26 per 420 mg multi-dose vial, 15% below the WAC of Herceptin. Actual costs to patients and providers for Mvasi and Kanjinti are anticipated to be lower.
At launch, Mvasi is priced 12% below the current Avastin Average Selling Price (ASP) and Kanjinti is priced 13% below the current Herceptin ASP. Both products will be available from both wholesalers and specialty distributors.
Mvasi and Kanjinti are the first products available from the Amgen and Allergan collaboration. Under the terms of the agreement, Amgen assumes primary responsibility for developing, manufacturing, and initially commercializing the oncology antibody products.